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ABSTRACT. The aim of this study was to determine the effect of reducing the number
of image guidance sessions and patient-specific target margins on the dose
distribution in the treatment of prostate cancer with helical tomotherapy. 20 patients
with prostate cancer who were treated with helical tomotherapy using daily
megavoltage CT (MVCT) imaging before treatment served as the study population.
The average geometric shifts applied for set-up corrections, as a result of co-
registration of MVCT and planning kilovoltage CT studies over an increasing number
of image guidance sessions, were determined. Simulation of the consequences of
various imaging scenarios on the dose distribution was performed for two patients
with different patterns of interfraction changes in anatomy. Our analysis of the daily
set-up correction shifts for 20 prostate cancer patients suggests that the use of four
fractions would result in a population average shift that was within 1 mm of the
average obtained from the data accumulated over all daily MVCT sessions. Simulation
of a scenario in which imaging sessions are performed at a reduced frequency and the
planning target volume margin is adapted provided significantly better sparing of
organs at risk, with acceptable reproducibility of dose delivery to the clinical target
volume. Our results indicate that four MVCT sessions on helical tomotherapy are
sufficient to provide information for the creation of personalised target margins and
the establishment of the new reference position that accounts for the systematic
error. This simplified approach reduces overall treatment session time and decreases
the imaging dose to the patient.
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Image guidance for daily localisation is becoming
increasingly used in conjunction with advanced delivery
techniques such as intensity-modulated radiation ther-
apy [1–11]. Pre-treatment imaging facilitates dose escal-
ation and organ at risk (OAR) sparing through a
reduction in the planning target volume (PTV) margin
customised to account for daily variation in patient
anatomy and set-up [12–30]. Helical tomotherapy (HT) is
an image guidance delivery platform combining on-
board megavoltage CT (MVCT) imaging and intensity-
modulated irradiation [31–34]. MVCT acquisition is used
routinely at our centre for daily image registration with
the reference kilovoltage CT (kVCT) for adjustment of
patient positioning prior to treatment. However, the
MVCT imaging, registration and patient repositioning
steps represent approximately 40% of the overall treat-
ment session time [35]. Therefore, optimisation of the
image localisation procedure is important for improved
(cost–benefit aspect) utilisation of the unit [36–38]. In
addition to positioning correction, the acquisition of
daily imaging also provides new opportunities for dose
adaptive radiotherapy (ART) [39, 40]. With the HT
platform, Planned AdaptiveH software (TomoTherapy
Inc. Madison, WI) is available that allows the delivered
dose distribution to be calculated using the MVCT study
and fluence sinograms of the same day. Adjustments of
structure contours can be included to reflect daily
anatomy changes and to study the impact of subsequent
adaptation of the plan. Adaptive planning applied either
retrospectively or prospectively using daily CT imaging
provides unique opportunities for delivery verification
and adaptive re-planning, respectively [41, 42].
Simulation of various dose delivery options allows for
assessment of the effects on the dose distribution of set-
up misalignment or internal anatomy changes.
Furthermore, adaptive planning, when used in conjunc-
tion with dose distribution recalculation, allows pro-
spective plan modification if a deformation or tumour
regression is considered clinically unacceptable.
Recently, the Orlando group reported an interesting
retrospective study of the residual localisation errors
with different imaging scenarios [43, 44], but they did not
explore the impact of different imaging options on the
accumulated dose delivery, as done in this work.
In this study, we used the daily set-up correction shifts
for 20 prostate cancer patients to explore opportunities
for safe reduction of the number of imaging procedures.
The goal was to find the minimal number of MVCT
sessions that allows for correction of the systematic error
in positioning specific to the patient. Information about
the random error obtained during these sessions allows
personalised PTVmargins to be created for the remaining
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treatment fractions. The Planned AdaptiveH software is
used for evaluation of the dose distribution with a
reduced number of imaging sessions. Optimal schedules
for imaging and/or plan adaptation for prostate cancer
cases are discussed.
Methods and patients
Patient population
In the current Hi-ARTH version (TomoTherapy Inc.
Madison, WI) of HT, the same linear accelerator is used
both for radiation treatment with 6 MV X-rays and for
MVCT imaging with 3.5 MV X-rays [34]. A mutual
information algorithm is used for co-registration of
kVCT and MVCT studies to detect daily position
corrections and visualise anatomy variations. The co-
registration images can be viewed in transverse, coronal
and sagittal cross-sections, and manual adjustments are
applied, if necessary. Since clinical use of HT com-
menced in our institution (September 2004), daily MVCT
studies have always preceded each radiation treatment,
and the geometric shifts made after the co-registration
step for each fraction of treatment have been recorded.
The results for the first 20 patients treated for prostate
cancer were reviewed for this study, incorporating a total
of 700 MVCT images. For all of the patients, the clinical
target volume (CTV) covered at minimum the whole
prostate gland and the PTV was expanded from the CTV
by adding an isotropic 10 mm margin.
Set-up corrections
In a recent paper, we analysed the average of the shifts
in the lateral xk, superior–inferior yk and anteroposterior
zk directions over k fractions (k 5 1,2,3,…, n, where n is
the total number of fractions) [45]. The average of patient
shifts over all n fractions (xn, yn,zn) would give the most
accurate average shift based on repeated daily imaging.
Based on the full set of acquired data for the 20 patients
treated, we simulated what deviations may be expected
in the case of a reduced number of imaging sessions
(k,n):
dx(k)~xk{xn,
dy(k)~yk{yn,
dz(k)~zk{zn:
8><
>:
ð1Þ
To choose the ‘‘optimal’’ number of imaging sessions,
denoted ‘‘i’’ in what follows, we analyse the values of d
(k) as a function of k for different directions (x, y, z) and
for different patients. When the average of d(k) over all
patients is below a given level of acceptability or
threshold level, this number of imaging sessions is
considered as optimal number i. Such a threshold level
can be set by comparing with the uncertainty of 3 mm in
prostate delineation by physicians on MVCT studies
during the co-registration step [46].
We define the interfraction motion tendency Y (i) by
using information from only the first i set-up shifts:
Y (i)~
Yx(i)~
1
i
Pi
m~1
xm{xij j
Yy(i)~
1
i
Pi
m~1
ym{yij j
Yz(i)~
1
i
Pi
m~1
zm{zij j
8>>>><
>>>>:
ð2Þ
This represents the average residual localisation error
when using the imaged fractions with a correction based
on the average shift over i fractions (these values will be
used as a modified set-up position (x0i , y
0
i ,z
0
i ) for the
remaining fractions without imaging). The parameters
Yx(i), Yy(i), Yz(i) contain patient-specific information
about the trends in interfraction motion and can be used
to calculate the margin (in most cases anisotropic)
around the CTV to create a ‘‘personalised’’ PTV for the
rest of the treatment.
The database of shifts made at the co-registration step
was used to evaluate what would be the residual error
using the actual shifts based on the daily MVCT studies
for treatment fractions (i+1) to n with respect to the
modified set-up position (x0i , y
0
i ,z
0
i ) calculated using the
MVCT studies of the first i fractions. The absolute value
of the vector shift
R(i,m)~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(xm{x0i )
2z(ym{y0i )
2z(zm{z0i )
2
q
,
m~ iz1ð Þ, iz2ð Þ,:::, n
ð3Þ
provides three-dimensional information on the actual
shift for fraction m, based on the MVCT study of this day
relative to the modified set-up position (x0i , y
0
i ,z
0
i ).
The averages over all fractions m from i+1 to n of the
actual shifts with respect to the modified set-up position
(x0i , y
0
i ,z
0
i ) are:
R~
Rx(i)~
1
n{i
Pn
m~iz1
xm{x
0
i
 
Ry(i)~
1
n{i
Pn
m~iz1
ym{y
0
i
  1ƒiƒn{1
Rz(i)~
1
n{i
Pn
m~iz1
zm{z
0
i
 
8>>>><
>>>>:
ð4Þ
These parameters have been calculated for all patients
included in this study.
In order to check the reliability of the prediction Y(k)
for patient interfraction motion, we calculated the
absolute values of difference (D(k)) between predicted
Y(k) (see Equation 2) and actual average shifts during
fractions (k+1) to n, R(k), (see Equation 4) for each
direction:
D(k)~
Dx(k)~ Rx(k){ Yx(k)
 
Dy(k)~ Ry(k){ Yy(k)
 
Dz(k)~ Rz(k){ Yz(k)
 
8><
>:
ð5Þ
for k varying from 2 to 9 for the 20 patients. Analysis of
these data may be used to choose the optimal number i of
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imaging sessions when D(i), the ‘‘error due to non-
imaging during fractions from (i+1) to n’’, is below an
acceptable threshold in all directions.
In this study, we had information about the target
position in all n fractions for 20 patients and so could
assess the inaccuracy of predicting interfraction motion
using residual deviations in the limited number (k) of
imaging sessions. We added the error margin given by
the difference D(k) between residual shift data obtained
during the first k fractions, Y(k), and the actual residual
shifts, R(k), observed in the remaining fractions.
Simulation of delivered dose distribution
Simulation of different imaging scenarios and verifica-
tion of the delivered dose were performed with the
Planned AdaptiveH (Tomotherapy Inc.) software. In the
first option, the MVCT studies of any fraction k were
placed, with respect to the planning kVCT study, in
accordance with the shifts applied by the therapists on
that day. The prostate volume and shape were assumed
not to change during treatment [47]; thus, the same
positioning shifts were applied to the CTV and PTV
contours determined by co-registration of the MVCT
studies. As the bladder and rectum volumes are subject
to daily changes, the outlines of the rectum and the
bladder were adapted by deformation of their contours
on each slice of the MVCT for each fraction. The dose
distribution calculated with the Planned AdaptiveH
software using the delivered fluence sinogram of the
day, pre-treatment MVCT images and adapted contours
is termed the ‘‘daily verification dose’’. Summing up the
daily verification doses for all fractions resulted in an
overall verification dose. In the second option, in order to
simulate the consequences for the dose distribution of a
reduced (k5i) imaging schedule, we summed up the
parameters obtained from dose–volume histograms
(DVHs) of the first i fractions, applying actual shifts
and adjusting contours as in the first option but, for the
days k.i, placing the daily MVCT image sets and the
structure contours to the modified set-up position
(x0i , y
0
i ,z
0
i ) representing the average shift during the first
i fractions. In this manner, we simulated the conse-
quences for the dose distribution of limiting the number
of imaging sessions. For the analysis, a DVH for each
fraction was obtained and the parameters of the dose
distribution for each fraction were summed for the whole
treatment course and compared with the planned goals.
In addition to providing set-up corrections, the
information about patient set-up shifts obtained during
first i imaging sessions could be useful ‘‘to personalise’’
the PTV margins for plan adaptation during the
remaining treatment (without CT imaging) from fraction
(i+1) to fraction n. Indeed, if we assume that the patient
would have the same trend to move in a particular
direction for the non-imaged residual fractions as in the
initial i fractions with MVCT imaging, we can adapt
(increase or reduce) the PTV size anisotropically and
thus preserve irradiation of the target with improved
sparing of the OARs [48–51]. With our database of
MVCT studies for patients with prostate cancer for all
fractions, we evaluated this assumption by using
Equations 1 and 3 for calculation of the average deviation
from the actual shifts with respect to the (x0i , y
0
i ,z
0
i )
position in the x, y and z directions.
Currently, there are several methods to define the PTV
margin; five of them were discussed by Hugo et al [51].
A working party of the British Institute of Radiology
provided the general approach to estimating sizes of
uncertainties and how to combine them in order to
define the PTV [52]. Chapter 5 of its report gives a
detailed description of systematic and treatment execu-
tion errors for calculation of PTV margins for the
prostate. The group in William Beaumont Hospital
proposed to construct a patient-specific PTV in the
adaptive treatment process for prostate cancer [53]. We
used the latter approach [51, 53] where the relation
Total randomerror~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(interfractionmotion)2z(intrafractionmotion)2
q ð6Þ
is used to determine the global movement of the prostate
by taking into account the inter- and intrafraction
motion. Published data on the prostate intrafractional
motion suggest that an additional internal margin of
more than 2.5 mm may be needed to account for this
motion [54–63], with reports of some cases where this
motion is greater than 1 cm [64, 65]. For our study, the
positional error owing to intrafraction motion was
considered to be 4 mm [66, 67].
Results
Patients
Two particular patients have been selected for special
attention in this group. Patient A, who was especially
large (135 kg), was chosen for this study because of the
large shifts observed during treatment: 9.8¡7.0 mm in
the lateral (x-axis) direction, 21.7¡2.1 mm in the long-
itudinal (superior–inferior, y-axis) direction and
11.4¡3.1 mm in the vertical (anteroposterior, z-axis)
direction with respect to the initial placement on external
marks. Patient B was selected because of the largest
average shift (by comparison with other patients) made
in the z direction (17.0¡2.6 mm) and moderate shifts in
other directions (1.6¡1.5 mm in x and 24.1¡1.2 mm in
y directions). Table 1 presents physical parameters, as
well as the prescription doses for these two ‘‘special’’
patients.
Optimal number of imaging sessions i
Daily shifts from MVCT/kVCT co-registration were
analysed for all fractions for all 20 patients in this study.
Some patients presented with significant variations in
correction shifts for individual treatment fractions, as
shown in Figure 1a for patient A. However, for most
patients, the shifts in each direction were more stable, as
was the case for patient B illustrated in Figure 1b.
Figure 2 illustrates the deviations d(k) of average shifts
calculated with a limited number of imaging sessions
from the ‘‘all fractions imaging’’ option. The daily shift
Image guidance with tomotherapy
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data for 20 prostate cancer patients were used to
calculate the population average of these deviations
[45]. Our analysis in the case of only four fractions (k54)
with MVCT imaging is presented in Table 2 and shows
that the population average of the deviation vector d(4) is
1.53 mm. Using only four fractions, 16/20, 15/20 and
11/20 patients demonstrated a deviation d(4) less than
1 mm in the x, y and z directions, respectively.
The R(4,m) values (see Equation 1) for each patient have
been calculated for the m fractions (m55 to n) and are
illustrated in Figure 3 for two of our patients. The average
overm fractions of these vectors, R(4), has been calculated
for each patient and plotted in Figure 4. The components
of the residual error R(4) (see Equation 4) for our set of 20
patients are given in Table 2. The average of the vector
shift around the position (x04, y
0
4,z
0
4), ,
R(4)., over the
population is 3.93¡1.29 mm; the maximum R(4) is
obtained for Patient A and is equal to 8.22 mm.
A reasonable trade-off between improving accuracy
and increasing workload points to the choice of the
optimal number of fractions with MVCT as k5i54, with
the maximal deviations D(4) below 3 mm in all directions
(see Table 2). In this case, parameters Yx(4), Yy(4) and
Yz(4) provide information about residual patient mobil-
ity in the x, y and z directions, respectively, once
systematic error is accounted for by using the average
reset position (x04, y
0
4,z
0
4) obtained for the first four MVCT
imaging sessions. The population average and maximum
values for components of D(4) are presented in Table 2.
Anisotropic PTV design
For Patient A, Yx(4)57.4 mm, Yy(4)52.0 mm and
Yz(4)52.7 mm, so the interfraction motion uncertainty
was estimated as 10.4 mm, 5.0 mm and 5.7 mm in the x,
y and z directions, respectively. Using Equation 6 and an
estimate of 4 mm for intrafraction target motion [61], the
margin for the CTV to obtain the PTV was rounded up to
12 mm, 7 mm and 7 mmmargins in x, y and z directions,
respectively, for our calculations.
For Patient B, the interfraction motion tendency Y(4)
was 3.6 mm in the x and y directions and 4.9 mm in the z
direction. These values led to a three-dimensional
anisotropic margins of 6 mm, 6 mm and 7 mm in the x,
y and z direction, respectively. In order to test the
sensitivity of the PTV margin on the method of their
construction, we have investigated the option where,
instead of deviation mean values (Equation 2), the
standard deviations of the shifts (representing random
error) with respect to the average are used for estima-
tions of the interfraction motion; very similar values for
the PTV margins were found.
Verification dose
For Patients A and B, new PTVs with anisotropic
margin values were created on the planning kVCT
studies, and new dose distributions were computed on
the tomotherapy planning station. Figure 6 shows initial
and adapted contours for the PTV of Patient B, and the
DVHs for plans with isotropic and adapted ‘‘personal-
ised’’ PTVs are presented in Figure 7 for this patient. The
delivery sinograms of both initial and adapted plans
were used to simulate the treatment with the adjusted
PTVs. In the case of Patients A and B, the results for
selected parameters of the dose distribution calculated
for initial plan are shown in the columns denoted
‘‘10 mm 3D PTV margin’’ in Table 3. Contours for the
Table 1. Patient characteristics and planning objectives
Patient Age
(years)
Weight
(kg)
Height
(cm)
Prescription in 35 fractions
A 69 135 163 73 Gy for 95% of the GTV (2.08 Gy/fraction)
70 Gy for 95% of the PTV70 (around the prostate) (2.00 Gy/fraction)
54 Gy for 95% of the PTV54 (around the seminal vesicles) (1.54 Gy/fraction)
B 75 102 167 73 Gy for 95% of the GTV and PTV (around the prostate) (2.08 Gy/fraction)
PTV, planning target volume; GTV, gross tumour volume.
(a) (b)
Figure 1. Set-up shifts obtained after matching megavoltage CT and kilovoltage CT studies on different days for Patients A (a)
and B (b) in three directions.
G Beldjoudi, S Yartsev, G Bauman et al
244 The British Journal of Radiology, March 2010
bladder and rectum were adjusted of each daily MVCT,
resulting in similar average bladder (144 cm3 and
146 cm3) and rectum (49 cm3 and 48 cm3) volumes for
Patients A and B, respectively.
For patient A, the minimum dose to the CTV in the
simulation scenario with i54 is only 0.7 Gy less than the
planned value and is still clinically acceptable. The
rectum receives a lower dose than planned owing to
predominant shifts in the lateral direction and the
contour adaptation. The bladder D15% dose is higher by
3.2 Gy than in the case of daily imaging but is still below
the threshold fixed by the Radiation Therapy Oncology
Group (RTOG) (bladder D15%580 Gy).
For Patient B, the CTV irradiation in the case of
imaging for the four first fractions is almost the same as
that planned. In the new plan, the bladder receives a
higher dose (but still below the RTOG constraint) and the
rectum has better sparing.
For the 20 prostate cancer patients in this study, the
point dose metrics have been found to be very close
(within ¡2%) to the values obtained in the initial plans,
proving the efficiency of image guidance with daily
MVCT.
Discussion
The choice of the number of imaging sessions i54
appears to be a good trade-off between MVCT workload
and the value of the average residual error d(4) after
using a standardised shift (modified set-up position)
based on a reduced number of MVCT images over the 20
patients, which is significantly less than 2 mm in all three
directions (see Table 2). A 2 mm value appears accept-
able if compared with the error of 3 mm in the prostate
detection by the physician on the MVCT studies during
the co-registration step [46]. Amer et al [29] and de Boer
and Heijmen [30] have found that three imaging days
provide an effective off-line correction of systematic
positional errors. For image guidance with cone-beam
CT, Nairz et al [6] analysed the data from six initial
imaging sessions and concluded that the gain of accuracy
was the largest during the first three sessions. Bortfeld et
al [68] determined that four is the optimal number for
measuring set-up errors by minimising the expectation
value of the total quadratic set-up error taken over all
fractions. Hoogeman et al [49] also favoured four
imaging sessions.
To determine the significance of the PTV adaptation, a
simulated dose distribution was re-calculated with
Planned AdaptiveH software. There are several approaches
to PTV margin construction [14, 19, 27, 48, 51–54, 65, 69].
We have no intention of entering into a debate over which
approach to the PTV margin creation is preferred. The
stress is on the ability to diminish the number of imaging
sessions and the ability of Planned AdaptiveH software to
check the dosimetric consequence of such a limitation. The
choice of the way in which to create the PTV margin is
defined by the accepted clinical practice in each institution.
We have chosen the margins based on Equation 6 to take
into account both intrafraction motion and patient-specific
(a) (b)
Figure 3. Set-up shifts with respect to the modified reference position (x04, y
0
4,z
0
4) defined as the average shift over the first four
fractions for Patients A (a) and B (b).
Figure 2. Examples for two patients of deviation d(k). These
represent the average shift over k fractions minus the
average shift over all n fractions, for different directions.
Image guidance with tomotherapy
The British Journal of Radiology, March 2010 245
information about his/her tendency for interfraction
motion given by Equation 2. The effect of the use of
personalised PTV margins is presented in Table 3 for
Patients A and B, with a comparison to the case of an
isotropic 10 mm PTV margin. For Patient A, comparing
the plans made with an anisotropic (specific for this
patient) margin and a three-dimensional isotropic 10 mm
margin shows that the use of an adapted PTV allows better
sparing for both the bladder and the rectum. The table also
presents the parameters obtained by simulating the case
with daily imaging for the first four fractions, patient
repositioning to (x04, y
0
4,z
0
4), and treatment without MVCT
scanning for the remaining fractions. The adapted PTV
shows a slight decrease in CTV coverage by only 0.9 Gy
compared with what would be achieved with daily
imaging (comparison between columns seven and six in
Table 3). Owing to an interfraction motion tendency to
shift this patient in the negative z direction, the rectum
receives more dose (but still within the RTOG constraints)
and the bladder is better spared.
For Patient B, the comparison made between columns
7 and 6 (Table 3) shows good coverage of the CTV
(difference of 0.2 Gy with the plan) and less dose to both
the rectum and the bladder by using an adapted PTV. As
discussed by Yan et al [53], a PTV adapted for the
majority of the treatment fraction may be used either for
dose escalation to the target with rectum isotoxicity or
for improved sparing of OARs.
Different parameters were evaluated for each of the
simulation scenarios, with i ranging from 1 to 9, and
compared with what was initially planned and accepted
clinically. The following parameters were evaluated:
D99% for the CTV; D99% for the PTV; D7cc, D30cc and D15%
for the bladder; and D15% and D15cc for the rectum. We
Figure 4. Average over fractions 5 to
n of the three-dimensional displace-
ments R(4) with respect to the mod-
ified reference position (x04, y
0
4,z
0
4) for
20 prostate cancer patients.
Table 2. Population averages and maximum values for different quantities introduced in Equations 1, 4 and 5 to measure the
uncertainties introduced by a reduced number of imaging sessions
Direction d(4) (mm) Max d(4) (mm) R(4) (mm) Max R(4) (mm) D(4) (mm) Max D(4) (mm)
x 0.89¡0.93 3.15 2.05¡1.34 6.62 0.85¡0.82 2.15
y 0.65¡0.47 1.83 1.63¡0.44 2.77 0.65¡0.484 2.09
z 1.12¡0.86 3.87 2.11¡0.78 4.37 0.83¡0.61 2.44
Table 3. Dose–volume histogram parameters (Gy) for treatments with daily imaging and for a simulated option with imaging
for four fractions followed by the patient positioned on (x04, y
0
4,z
0
4) for fractions 5 to n. A comparison of cases with isotropic
10 mm and adapted (anisotropic) PTV margins
Patient Structure Parameter 10 mm 3D PTV margins Adapted 3D PTV margins
Planning dose Simulation dose Planning dose Simulation dose
A GTV D99% 72.2 71.5 72.0 71.1
PTV70 D99% 69.5 57.9 69.1 58.1
Bladder D15% 61.5 64.7 58.5 60.6
D7cc 72.1 72.1 69.4 66.8
D30cc 63.7 51.2 59.5 58.1
Rectum D15% 68.5 66.7 62.6 63.4
D15cc 60.3 59.0 56.9 56.9
B GTV D99% 74.0 73.97 72.8 72.6
PTV D99% 69.4 62.2 71.1 58.4
Bladder D15% 72.3 74.1 66.1 70.2
D7cc 74.5 75.5 73.7 74.8
D30cc 68.3 71.4 61.4 65.6
Rectum D15% 70.3 64.9 64.9 60.8
D15cc 52.3 52.1 50.6 50.9
PTV, planning target volume; 3D, three-dimensional; GTV, gross tumour volume.
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(a)
(b)
(c)
Figure 5. Absolute values of the
difference D(k) between predicted
average shifts, Y(k), and observed
average shifts, R(k), for (a) x, (b) y
and (c) z directions. Data are for the
20 patients included in this study.
Large circles denote data for Patient
A and large diamonds data for
Patient B.
Image guidance with tomotherapy
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Figure 6. The initial planning tar-
get volume (PTV) with isotropic
10 mm margins (red lines) and
adapted PTV with personalised an-
isotropic margins (turquoise lines)
for Patient B.
(a)
(b)
Figure 7. Comparison of dose–volume histograms in (a) initial and (b) adapted plans for Patient B.
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note that, owing to daily changes of the prostate and
rectum volumes, the parameter D15% is less informative
than the absolute fixed volumes D7cc and D30cc for the
bladder and D15cc for the rectum. The clinical signifi-
cance of D7cc and D30cc for the bladder was discussed by
Harsolia et al [70], whereas the significance of D15cc for
the rectum was proposed by Kupelian et al [71] as an
indicator of rectal bleeding. We should note that the
daily verification dose calculated with Planned
AdaptiveH does not take into account the effect of organ
deformation [72]; therefore, point dose metrics for the
overall verification dose (Dmax, Dmin, D5cc, etc.) may not
be accurate when summed in this fashion. This is likely
to be more of an issue for bladder and rectum volumes
than for the prostate, which is stable in volume.
The question of imaging dose is currently under active
discussion [73, 74]. In our practice, each MVCT delivers
,1.2 cGy per acquisition (with daily imaging of 42 cGy
or ,0.6% of prescription), which is less than MV portal
images and of the same order as the dose from cone
beam CT [74]. Our evaluation of the optimal number of
imaging sessions offers a compromise between delivery
precision and shortened in-room time and lower total
imaging dose to the patient.
In the future it would be interesting to explore a
correlation between a patient’s specific features and the
interfraction prostate motion. Indeed, if some physical
particularities could be identified (weight, prostate size,
prostate shape, etc.) as a predictive factor of the patient’s
future interfraction motion, some groups of patients
could be identified a priori in order to adapt different
imaging protocols specific to each cohort. Patient A, for
example, was the heaviest patient of the group of 20 and
was suffering from rectal bleeding and strong pain in the
legs owing to arthritis. These few elements could explain
why this patient had such irregularities in his positioning
on the couch. Studies on a larger patient database would
be beneficial (especially to answer the question of
adequate threshold value for registration shift correc-
tion), and more simulated dose distribution calculations
for various imaging scenarios need to be done before
optimal imaging and treatment options for a particular
patient can be determined.
Conclusions
We have shown that only four sessions of MVCT
imaging on a tomotherapy unit are normally sufficient to
account for the systematic set-up error, with clinically
acceptable accuracy for prostate radiotherapy. Moreover,
the daily shifts in three directions registered during these
first four fractions allow us to determine the general
tendency of a patient to move in a particular direction
and thus permit the characterisation of the interfraction
motion specific to this patient. Based on these character-
istics of the interfraction motion, new ‘‘personalised’’
PTV margins can be created to assure the improved
irradiation of the CTV and/or sparing of the organs at
risks. The use of the Planned AdaptiveH software allowed
the evaluation of the effects of daily MVCT imaging vs
scenarios of the limited number of imaging sessions and
adaptation of the PTV margin.
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